Neurocrine Biosciences, Inc.

Boehringer Ingelheim International Gmbh

Neil Ashweek

Timothy Richard Coon

Martin W Rowbottom

Warren Stanfield Wade

Mi Chen

Todd Ewing

Yun-Fei Zhu

Nicole Harriott

Graham Beaton

Wanlong Jiang

Willy Moree

Liren Zhao

Richard B Lowe

Nicole Smith

Frank Himmelsbach

Elke Langkopf

Manisha Moorjani

Bernd Nosse

John Patrick Williams

Deborah Slee

Armin Heckel

Andreas Blum

Jinghua Yu

Matthias Eckhardt

Chen Chen

Brian Dyck

Junko Tamiya

Steffen Breitfelder

Troy Vickers

Bernd Wellenzohn

Joe Anh Tran

Collin Regan

Sha Luo

Gordon Raphael Loewen

John P Williams

Florence Jovic

Juan Pablo Cueva-Garcia

Evan Smith

Richard Lowe

Warren Wade

Martin Rowbottom

The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.

GPR52 modulators and methods of use

Compounds are provided herein, as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).

CRF receptor antagonists and methods of use

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: wherein Ris as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.

[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure: wherein R, R, Rand n are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound provided herein in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for treating neurological disorders in a subject in need thereof.

Substituted triazoles and methods relating thereto

[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Compounds of formula I wherein R, L, n, HetAr, and HetArare as defined herein, and salts thereof, pharmaceutical compositions containing these compounds, and methods for treating diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR119, such as diabetes, dislipidemia, or obesity, by administering to a patient in need thereof these compounds or a pharmaceutically acceptable salt thereof.

N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof

[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

The present invention relates to compounds of general formula (I), wherein R, L, L, (Het)Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR1 19 receptor and modulate its activity. 

N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof

Growing community of inventors

Escondido, CA, United States of America

Neil Ashweek